KURA
Bullish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Financial indicators Unavailable or mixed. Current ratio 6.06 · operating margin -450% — readings disagree
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
ACHAT TOTAL: 200000 titres (~2351000 USD) VENTE TOTALE: 35832 titres (~449344 USD)
- Insiders
- Bair Teresa BrophyPowl Brian T.WILSON TROY EDWARD
- Total bought
-
$2,351,000
Avg buy (VWAP, 90d window) $11.76 vs last close $11.04 (-6.1%)
- Total sold
-
$449,344
Avg sell (VWAP, 90d window) $12.54 vs last close $11.04 (-12.0%)
- Last activity
- 2026-08-24
- Liquidity
- Liquid $21,244,360/day · 20d vol
- Last synced
-
2026-09-23 21:10:40
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-24 | WILSON TROY EDWARD | Buy | 100,000 | $12.39 | $1,239,000 | Form 4 |
| 2026-08-21 | Powl Brian T. | Sell | 4,345 | $11.89 | $51,663 | Form 4 |
| 2026-08-19 | Bair Teresa Brophy | Sell | 31,487 | $12.63 | $397,681 | Form 4 |
| 2026-08-17 | WILSON TROY EDWARD | Buy | 100,000 | $11.12 | $1,112,000 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bullish signalScored 2026-09-20
KURA presents a compelling event-driven setup driven by a high-conviction insider cluster buy (including CEO participation) coinciding with the KOMZIFTI commercial launch and a 37.6% one-month price surge, suggesting…
The first sentence of the analysis written for KURA on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 99.9% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -410.3% | -316.1% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -408.7% | -314.6% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -449.9% | -358.5% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -412.5% | -319.1% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -412.9% | -322.9% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -412.9% | -322.9% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -412.9% | -322.9% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 6.058 | 9.463 | 12.264 | 18.557 | 23.259 | |
| Quick Ratio | 6.055 | 9.463 | 12.264 | 18.557 | 23.259 | |
| Solvency Ratio | -0.492 | -0.500 | -2.938 | -3.749 | -4.734 | |
| Cash Ratio | 1.275 | 2.852 | 1.058 | 2.153 | 4.038 | |
| Price To Earnings Ratio | -3.267 | -4.312 | -6.913 | -6.113 | -7.107 | |
| Price To Earnings Growth Ratio | -0.057 | 1.495 | -2.807 | -2.007 | -0.429 | |
| Forward Price To Earnings Growth Ratio | -0.057 | 1.495 | -2.807 | -2.007 | -0.429 | |
| Price To Earnings Diluted Ratio | -3.267 | -4.312 | -6.913 | -6.113 | -7.107 | |
| Price To Earnings Diluted Growth Ratio | -0.057 | 1.495 | -2.807 | -2.007 | -0.429 | |
| Price To Book Ratio | 5.231 | 1.814 | 2.651 | 1.978 | 1.834 | |
| Price To Sales Ratio | 13.499 | 13.928 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -12.886 | 5.607 | -8.425 | -7.511 | -8.789 | |
| Price To Operating Cash Flow Ratio | -14.221 | 5.587 | -8.436 | -7.553 | -8.885 | |
| Debt To Assets Ratio | 0.028 | 0.022 | 0.038 | 0.031 | 0.013 | |
| Debt To Equity Ratio | 0.117 | 0.040 | 0.043 | 0.033 | 0.014 | |
| Debt To Capital Ratio | 0.105 | 0.039 | 0.041 | 0.032 | 0.013 | |
| Long Term Debt To Capital Ratio | 0.053 | 0.016 | 0.023 | 0.021 | 0.000 | |
| Financial Leverage Ratio | 4.240 | 1.838 | 1.130 | 1.086 | 1.054 | |
| Working Capital Turnover Ratio | 0.107 | 0.101 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -0.548 | 1.706 | -3.540 | -4.575 | -4.656 | |
| Operating Cash Flow Sales Ratio | -0.949 | 2.493 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | 0.996 | 1.001 | 1.006 | 1.011 | |
| Debt Service Coverage Ratio | -182.620 | -40.586 | -96.987 | -588.873 | -312.787 | |
| Interest Coverage Ratio | -200.814 | -119.330 | -107.039 | -610.764 | -317.048 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 51.522 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.131 | 8.094 | -7.257 | -7.848 | -15.207 | |
| Capital Expenditure Coverage Ratio | -9.650 | 284.570 | -743.000 | -175.818 | -91.152 | |
| Dividend Paid And Capex Coverage Ratio | -9.650 | 284.570 | -743.000 | -175.818 | -91.152 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.836 | -3.201 | -6.875 | -5.885 | -6.526 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 99.9% | ▼-0.1% | ▲59.9% |
| Ebit Margin | -410.3% | ▼-94.1% | ▼-265.0% |
| Ebitda Margin | -408.7% | ▼-94.2% | ▼-264.1% |
| Operating Profit Margin | -449.9% | ▼-91.4% | ▼-288.2% |
| Pretax Profit Margin | -412.5% | ▼-93.4% | ▼-266.2% |
| Continuous Operations Profit Margin | -413.0% | ▼-90.1% | ▼-265.8% |
| Net Profit Margin | -413.0% | ▼-90.1% | ▼-265.8% |
| Bottom Line Profit Margin | -413.0% | ▼-90.1% | ▼-265.8% |
| Current Ratio | 6.058 | ▼-3.404 | ▼-7.862 |
| Quick Ratio | 6.055 | ▼-3.408 | ▼-7.865 |
| Solvency Ratio | -0.492 | ▲0.008 | ▲1.990 |
| Cash Ratio | 1.275 | ▼-1.577 | ▼-1.000 |
| Price To Earnings Ratio | -3.267 | ▲1.045 | ▲2.275 |
| Price To Earnings Growth Ratio | -0.057 | ▼-1.552 | ▲0.704 |
| Forward Price To Earnings Growth Ratio | -0.057 | ▼-1.552 | ▲0.704 |
| Price To Earnings Diluted Ratio | -3.267 | ▲1.045 | ▲2.275 |
| Price To Earnings Diluted Growth Ratio | -0.057 | ▼-1.552 | ▲0.704 |
| Price To Book Ratio | 5.231 | ▲3.417 | ▲2.530 |
| Price To Sales Ratio | 13.499 | ▼-0.428 | ▲8.014 |
| Price To Free Cash Flow Ratio | -12.886 | ▼-18.492 | ▼-6.485 |
| Price To Operating Cash Flow Ratio | -14.221 | ▼-19.808 | ▼-7.519 |
| Debt To Assets Ratio | 0.028 | ▲0.006 | ▲0.001 |
| Debt To Equity Ratio | 0.117 | ▲0.077 | ▲0.068 |
| Debt To Capital Ratio | 0.105 | ▲0.067 | ▲0.059 |
| Long Term Debt To Capital Ratio | 0.053 | ▲0.036 | ▲0.030 |
| Financial Leverage Ratio | 4.240 | ▲2.402 | ▲2.371 |
| Working Capital Turnover Ratio | 0.107 | ▲0.006 | ▲0.066 |
| Operating Cash Flow Ratio | -0.548 | ▼-2.254 | ▲1.775 |
| Operating Cash Flow Sales Ratio | -0.949 | ▼-3.442 | ▼-1.258 |
| Free Cash Flow Operating Cash Flow Ratio | 1.104 | ▲0.107 | ▲0.080 |
| Debt Service Coverage Ratio | -182.620 | ▼-142.035 | ▲61.751 |
| Interest Coverage Ratio | -200.814 | ▼-81.484 | ▲70.185 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-51.522 | ▼-10.304 |
| Operating Cash Flow Coverage Ratio | -3.131 | ▼-11.226 | ▲1.939 |
| Capital Expenditure Coverage Ratio | -9.650 | ▼-294.220 | ▲137.360 |
| Dividend Paid And Capex Coverage Ratio | -9.650 | ▼-294.220 | ▲137.360 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.836 | ▲0.365 | ▲2.228 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $911.0M | $750.5M | $1.05B | $831.3M | $928.9M | |
| Enterprise value | $782.3M | $542.6M | $1.03B | $793.6M | $845.1M | |
| EV / Sales | 11.59x | 10.07x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -12.21x | 4.04x | -8.28x | -7.21x | -8.08x | |
| EV / Free cash flow | -11.07x | 4.05x | -8.26x | -7.17x | -8.00x | |
| EV / EBITDA | -2.84x | -3.20x | -6.88x | -5.88x | -6.53x | |
| Net debt / EBITDA | 0.47x | 1.23x | 0.13x | 0.28x | 0.65x | |
| Current ratio | 6.06x | 9.46x | 12.26x | 18.56x | 23.26x | |
| Income quality | 0.23x | -0.77x | 0.82x | 0.81x | 0.80x | |
| Graham net-net | $1 | $4 | $5 | $6 | $7 | |
| Tax burden | 100.1% | 101.2% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.5% | 101.0% | 101.0% | 100.2% | 100.3% | |
| Working capital | $591.7M | $666.1M | $397.2M | $422.4M | $499.8M | |
| Invested capital | $606.8M | $673.6M | $406.1M | $428.8M | $508.1M | |
| Return on assets | -37.7% | -22.9% | -34.0% | -29.8% | -24.4% | |
| Operating ROA | -40.5% | -32.0% | -36.6% | -28.2% | -22.2% | |
| Return on tangible assets | -37.7% | -22.9% | -34.0% | -29.8% | -24.4% | |
| Return on equity | -160.0% | -42.1% | -38.4% | -32.3% | -25.8% | |
| Return on invested capital | -48.8% | -28.2% | -39.9% | -32.2% | -25.5% | |
| Return on capital employed | -48.9% | -28.4% | -40.1% | -32.4% | -25.7% | |
| Earnings yield | -30.6% | -23.2% | -14.5% | -16.3% | -14.0% | |
| Free cash flow yield | -7.8% | 17.8% | -11.9% | -13.3% | -11.4% | |
| Capex / Op. cash flow | -10.4% | 0.4% | -0.1% | -0.6% | -1.1% | |
| Capex / Depreciation | -89.0% | 55.7% | 19.8% | 82.5% | 205.6% | |
| Capex / Sales | 9.8% | 0.9% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 177.8% | 143.1% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 372.1% | 315.4% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 55.0% | 62.9% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 68d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 32126d | 0d | 989d | 0d | 0d | |
| Operating cycle | 2713d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -29414d | 0d | -989d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+21.4%EV / Sales ▲+15.1%EV / EBITDA ▲+11.4%EV / Op. cash flow ▼-16.252Earnings yield ▼-0.074
Profitability
Return on equity ▼-1.180Return on assets ▼-0.149Return on invested capital ▼-0.206Return on capital employed ▼-0.205Operating ROA ▼-0.086Income quality ▲+1.002Tax burden ▼-0.011
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▲+0.090R&D / Sales ▲+0.566
Balance-sheet strength
Current ratio ▼-3.404Net debt / EBITDA ▼-0.760Working capital ▼-74428000.000Invested capital ▼-66756000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-1.9%EV / Sales n/aEV / EBITDA ▲+56.5%EV / Op. cash flow ▼-4.129Earnings yield ▼-0.165
Profitability
Return on equity ▼-1.343Return on assets ▼-0.133Return on invested capital ▼-0.232Return on capital employed ▼-0.232Operating ROA ▼-0.183Income quality ▼-0.571Tax burden ▲+0.001
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-17.201Net debt / EBITDA ▼-0.181Working capital ▲+91855000.000Invested capital ▲+98766000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Chris Jacobs | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-04 Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on September 1, 2026, the Compensation Committee of the Company''s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 48,450 shares of common stock to four (4) new employees under the Company''s 2023 Inducement Option Plan, as amended.
- 2026-09-01 KURA Stock Gains 37.6% in a Month: Here''s What You Need to Know Kura''s rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA''s gains.
- 2026-09-01 Kura Oncology to Participate in Three Investor Conferences in September SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m.
- 2026-08-31 Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company''s earnings prospects. This might drive the stock higher in the near term.
- 2026-08-27 Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
- 2026-08-26 Kura Oncology: ''Strong Buy'': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI''s Prospects Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI''s FDA approval and robust early commercial performance in relapsed/refractory NPM1-mutated AML. The company achieved $9.1M net product revenue in two quarters, marking a 57% sequential increase, and targets significant market expansion via first-line AML indications. Phase 3 KOMET-017 trial topline data in 2028 and two phase 1b KOMET-007 data readouts in 2H 2026 are key catalysts for pipeline expansion and valuation.
- 2026-08-25 Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026? The President and CEO acquired ~100,000 shares at $12.39 per share for a total transaction value of $1.2 million. The purchase increased the executive''s total equity holdings by 9%.
- 2026-08-25 Kura Oncology (KURA) CEO Purchases Shares Amid Positive KOMZIFTI Launch Metrics Kura Oncology (KURA) gained attention today as CEO Troy Wilson bought another 100,000 shares for about $1.2 million on August 24. This follows a previous purcha
- 2026-08-19 Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy? Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-18 Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect? The mean of analysts'' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.